- September 17, 2010
- Taiho Pharmaceutical Co., Ltd.
Antineoplastic ABRAXANE® to be Launched Friday, September 24
Taiho Pharmaceutical Co., Ltd., announced today that ABRAXANE® I.V. Infusion 100 mg, an antineoplastic for injectable suspension (paclitaxel protein-bound particles for injectable suspension, albumin-bound), has been added to the NHI price listing and will go on sale from Friday, September 24, 2010.
ABRAXANE® was developed by Los Angeles-based Abraxis BioScience, Inc., (NASDAQ: ABII). As a novel paclitaxel formulation for breast cancer treatment, ABRAXANE® features improved efficacy and safety as well as easier administration compared to solvent-based paclitaxel. Abraxis BioScience’s proprietary nab® technology could eliminate the need for steroids and other pre-medication for preventing hypersensitivity, which are required for solvent-based paclitaxel. In addition, ABRAXANE® shortens the infusion period to 30 minutes, thereby relieving the burden on patients and potentially improving the efficiency of outpatient chemotherapy.
ABRAXANE® was approved by the United States Food and Drug Administration in January 2005, and is currently approved in 41 countries. Taiho Pharmaceutical is confident that ABRAXANE® will offer better treatment options for patients suffering from breast cancer. The drug was approved in Japan on condition that surveillance of results of use will be conducted covering all cases from the launch until data are accumulated for a certain number of cases. Accordingly, Taiho Pharmaceutical intends to immediately begin collecting data relating to the drug’s efficacy and safety, and will take whatever measures are needed to ensure proper usage.
Abraxis BioScience, Inc.
Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company's portfolio includes chemotherapeutic compound (ABRAXANE), which is based on the company's proprietary tumor targeting technology known as the nab® platform. The first FDA approved product to use this nab platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer and is now approved in 41 countries. The company continues to expand the nab platform through a robust clinical program and deep product pipeline. Abraxis trades on the NASDAQ Global Market under the symbol ABII. For more information about the company and its products, please visit
|Product name||ABRAXANE® I.V. Infusion 100 mg|
|Date approved||July 23, 2010|
|Dosage and administration||The usual adult dosage is 260 mg/m2 of body surface area once daily, delivered via intravenous drip infusion over a 30-minute period, followed by washout period of at least 20 days. This constitutes one cycle, with administration being repeated. The dose may be reduced appropriately according to the patient's condition.|
|Condition for approval||A Surveillance of Results of Use shall be conducted covering all cases until data are|
Information in this news release was current as of the original release date.